297 related articles for article (PubMed ID: 32497151)
1. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G
PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151
[TBL] [Abstract][Full Text] [Related]
2. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
5. Distinct antinociceptive and conditioned behavioral effects are produced by individual cannabinoids and a cannabis-derived mixture.
Morris T; Cucinello-Ragland JA; Marks TJ; Prevost K; Glenn JF; Davenport GJ; Edwards S; Winsauer PJ
Pharmacol Biochem Behav; 2024 Feb; 235():173692. PubMed ID: 38128766
[TBL] [Abstract][Full Text] [Related]
6. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain.
Zhu YF; Linher-Melville K; Niazmand MJ; Sharma M; Shahid A; Zhu KL; Parzei N; Sidhu J; Haj C; Mechoulam R; Singh G
Br J Pharmacol; 2020 Jun; 177(12):2712-2725. PubMed ID: 31981216
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
10. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
Ross HR; Napier I; Connor M
J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
[TBL] [Abstract][Full Text] [Related]
12. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
13. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain.
Britch SC; Craft RM
J Pain; 2023 Jan; 24(1):98-111. PubMed ID: 36122809
[TBL] [Abstract][Full Text] [Related]
15. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol modulation of antinociceptive tolerance to Δ
Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
[TBL] [Abstract][Full Text] [Related]
17. Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model: A Pilot Study.
Stauch CM; Ammerman B; Sepulveda D; Aynardi MC; Garner MR; Lewis G; Morgan D; Dhawan A
Am J Sports Med; 2021 Jul; 49(9):2522-2527. PubMed ID: 34097540
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
19. Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats.
Javadi-Paydar M; Nguyen JD; Kerr TM; Grant Y; Vandewater SA; Cole M; Taffe MA
Psychopharmacology (Berl); 2018 Sep; 235(9):2541-2557. PubMed ID: 29907926
[TBL] [Abstract][Full Text] [Related]
20. Effect of cannabidiolic acid and ∆
Rock EM; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2018 Nov; 235(11):3259-3271. PubMed ID: 30225659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]